ChartRow logo
Data provided bySource: Twelve Data
UTHR
$584.10-0.64%
as of close, Nov 17, 2026
☾ AH $584.10 -0.64%
PeersNBIXZTSVTRSTAKRDYHLN
Share this page

UTHR financial statements

The full income statement, balance sheet, and cash-flow statement for United Therapeutics Corporation (UTHR), plus valuation ratios — straight from SEC filings. Switch between annual, quarterly, and trailing-twelve-month figures, pick how far back to look, and flip the time order. Every line has a trend sparkline.

Financial overview#

Revenue

5Y CAGR +16.5%10Y CAGR +8.1%YoY +4.1%
$3.2B TTM$832.5M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Gross profit

5Y CAGR +15.3%10Y CAGR +7.2%YoY +5.0%
$2.8B TTM$733.4M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating income

5Y CAGR +20.2%10Y CAGR +7.9%YoY −20.8%
$1.3B TTM$307.8M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Net income

5Y CAGR +21.0%10Y CAGR +7.4%YoY −23.6%
$1.2B TTM$258.6M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

EPS (diluted)

5Y CAGR +19.3%10Y CAGR +8.2%YoY −20.3%
$26.53 TTM$5.71 Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Operating cash flow

5Y CAGR +15.6%10Y CAGR +15.1%YoY −45.5%
$1.4B TTM$306.5M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Capital expenditure

5Y CAGR +54.4%10Y CAGR +26.5%YoY −14.2%
$562.4M TTM$180.7M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Free cash flow

5Y CAGR +8.4%10Y CAGR +12.1%YoY −64.2%
$867.2M TTM$125.8M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Shares (diluted)

5Y +7.4%10Y −6.4%YoY −4.2%
46.4M TTM45.3M Q3 '26
FY15FY16FY17FY18FY19FY20FY21FY22FY23FY24FY25TTM
Q4 '16Q1 '17Q2 '17Q3 '17Q4 '17Q1 '18Q2 '18Q3 '18Q4 '18Q1 '19Q2 '19Q3 '19Q4 '19Q1 '20Q2 '20Q3 '20Q4 '20Q1 '21Q2 '21Q3 '21Q4 '21Q1 '22Q2 '22Q3 '22Q4 '22Q1 '23Q2 '23Q3 '23Q4 '23Q1 '24Q2 '24Q3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Every UTHR chart on Trends →

Shares outstanding (point-in-time)

2024-09 44.6M2024-12 44.9M2025-03 45.1M2025-06 45.2M2025-09 43.1M2025-12 43.8M2026-03 42.4M2026-06 42.9M2026-09 42.6M-4.6% over 8 periods

SEC-filed end-of-period counts (cover pages and balance sheets, split-adjusted) — the series realized buyback yield is computed from. The weighted-average share lines in the statements below lag these by design: an average over the year sits near the midpoint of an ongoing buyback.

PeriodRangeOrderChangeFiguresAs-reported fiscal years.
Line itemTrendFY2025FY2024FY2023FY2022FY2021
Income Statementas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Revenue3.18B+10.6%2.88B+23.6%2.33B+20.2%1.94B+14.9%1.69B+13.6%
2.80B+9.0%2.57B+24.0%2.07B+16.0%1.78B+14.2%1.56B+13.7%
Cost of revenue384M+24.1%310M+20.3%258M+69.9%152M+23.8%123M+13.3%
Research & development550M+14.3%481M+17.9%408M+26.4%323M-40.2%540M+51.0%
Selling, general & administrative756M+6.5%710M+48.8%477M-1.0%482M+3.2%467M
Amortization of intangibles900K+0.0%900K+200.0%300K+200.0%100K+0.0%100K-50.0%
Operating income1.49B+8.4%1.38B+16.2%1.18B+20.9%980M+76.2%556M-6.4%
Interest expense19.5M-54.5%42.9M-27.7%59.3M+83.0%32.4M+74.2%18.6M-20.9%
Interest & investment income192M-3.6%199M+22.4%163M+260.0%45.2M+170.7%16.7M-41.6%
Other non-operating income48.9M+743.1%5.80M+141.4%-14.0M+65.2%-40.2M-195.3%42.2M-14.4%
Pre-tax income1.71B+11.4%1.54B+20.8%1.27B+34.1%951M+60.1%594M-7.0%
Income tax379M+10.3%344M+18.8%290M+29.6%223M+89.1%118M-4.8%
1.33B+11.7%1.20B+21.4%985M+35.4%727M+52.9%476M-7.6%
Net income to common1.33B+11.7%1.20B+21.4%985M+35.4%727M+52.9%476M-7.6%
$27.86+13.1%$24.64+24.4%$19.81+32.1%$15.00+49.1%$10.06-12.8%
EPS (basic)$30.13+14.0%$26.44+25.7%$21.04+31.7%$15.98+50.8%$10.60-9.0%
Weighted-avg shares (basic)44.3M-2.0%45.2M-3.4%46.8M+2.9%45.5M+1.3%44.9M+1.6%
Weighted-avg shares (diluted)47.9M-1.2%48.5M-2.4%49.7M+2.5%48.5M+2.5%47.3M+6.1%
Balance Sheetas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
3.70B-4.4%3.87B+9.1%3.55B+5.0%3.38B+45.5%2.32B+7.2%
Cash & equivalents1.56B-8.3%1.70B+40.5%1.21B+25.6%961M+7.4%895M+21.1%
Short-term investments1.36B-13.2%1.57B-12.1%1.79B-4.9%1.88B+81.2%1.04B-5.5%
Accounts receivable350M+25.4%279M+0.1%279M+26.5%220M+10.9%199M+26.2%
Inventory183M+16.0%158M+41.2%112M+9.6%102M+8.7%93.8M+8.4%
Other current assets249M+46.7%170M+2.1%166M-24.2%219M+118.3%100M+13.7%
7.88B+7.0%7.36B+2.7%7.17B+18.6%6.04B+16.9%5.17B+12.0%
Property, plant & equipment1.73B+41.5%1.22B+16.9%1.05B+21.3%862M+10.3%781M+6.7%
Goodwill32.3M+0.0%32.3M-4.2%33.7M+20.4%28.0M+0.0%28.0M+0.0%
Long-term investments1.78B+20.4%1.48B-22.8%1.91B+45.1%1.32B-20.2%1.65B+43.5%
Deferred tax assets358M-22.0%458M+16.1%395M+20.5%328M+25.1%262M+9.8%
Other non-current assets197M-11.3%222M+46.3%152M+32.8%114M+5.6%108M-36.3%
561M-24.0%738M-8.2%804M+134.4%343M+12.4%305M-5.5%
Accounts payable7.10M+18.3%6.00M+7.1%5.60M+36.6%4.10M+7.9%3.80M-7.3%
Accrued liabilities488M+41.7%345M+15.6%298M+29.6%230M+31.7%175M-6.6%
Short-term & current debt0.00-100.0%300M-25.0%400M0.00—
Other current liabilities72.6M-22.4%93.6M+31.8%71.0M+118.5%32.5M+14.4%28.4M-28.1%
784M-14.8%920M-22.2%1.18B-5.3%1.25B+3.1%1.21B-0.8%
Long-term debt—0.00-100.0%300M-62.5%800M+0.0%800M+0.0%
Other non-current liabilities223M+22.7%182M+133.8%77.8M-25.6%105M-0.2%105M+8.6%
7.10B+10.1%6.44B+7.7%5.98B+24.8%4.80B+21.2%3.96B+16.6%
Preferred stock0.000.000.000.000.00
Common stock800K+0.0%800K+14.3%700K+0.0%700K+0.0%700K+0.0%
Additional paid-in capital2.80B+3.7%2.70B+5.9%2.55B+6.7%2.39B+6.4%2.25B+4.5%
Retained earnings8.56B+18.5%7.22B+19.8%6.03B+19.5%5.04B+16.9%4.32B+12.4%
Treasury stock4.26B+22.6%3.47B+34.7%2.58B+0.0%2.58B+0.0%2.58B+0.0%
Accumulated other comprehensive income900K+126.5%-3.40M+73.4%-12.8M+76.9%-55.5M-141.3%-23.0M-62.0%
Total equity incl. non-controlling7.10B+10.1%6.44B+7.7%5.98B+24.8%4.80B+21.2%3.96B+16.6%
Total liabilities & equity7.88B+7.0%7.36B+2.7%7.17B+18.6%6.04B+16.9%5.17B+12.0%
Common shares issued76.5M+1.9%75.0M+1.8%73.7M+1.4%72.7M+1.3%71.7M+0.8%
Common shares outstanding43.6M-2.7%44.8M-4.7%47.0M+2.2%46.0M+2.0%45.1M+1.3%
Shares outstanding (cover)43.8M-2.4%44.9M-4.6%47.1M+1.6%46.3M+2.6%45.1M+1.3%
Treasury shares32.8M+8.8%30.2M+13.3%26.6M+0.0%26.6M+0.0%26.6M+0.0%
Cash Flowas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
1.56B+17.6%1.33B+35.7%978M+21.9%803M+34.2%598M-20.8%
Depreciation & amortization85.6M+18.1%72.5M+36.3%53.2M+3.7%51.3M+2.8%49.9M+0.0%
Intangible amortization900K+0.0%900K+200.0%300K+200.0%100K+0.0%100K-50.0%
Share-based compensation148M+2.6%144M+268.3%39.1M-63.4%107M-22.9%139M-15.4%
Deferred income taxes97.7M+252.4%-64.1M+0.5%-64.4M-26.8%-50.8M-170.2%-18.8M-79.0%
Change in receivables70.9M+17625.0%400K-99.3%58.5M+169.6%21.7M-47.5%41.3M+588.3%
Change in inventory52.6M+12.2%46.9M+244.9%13.6M+1.5%13.4M+78.7%7.50M+172.8%
-551M-232.1%417M+158.0%-720M+11.3%-812M-66.7%-487M+34.1%
Capital expenditure521M+111.2%247M+7.0%230M+66.0%139M+14.9%121M+103.7%
Free cash flow1.04B-3.7%1.08B+44.5%748M+12.6%664M+39.0%477M-31.4%
Acquisitions0.000.00-100.0%89.2M0.000.00
Sales/maturities of investments1.58B+3.1%1.54B-28.1%2.14B+109.2%1.02B-25.4%1.37B-10.1%
Proceeds from sale of PP&E———0.000.00-100.0%
-1.15B+8.4%-1.25B-10444.5%-11.9M-115.8%75.4M+68.3%44.8M+365.1%
Long-term debt issued0.000.000.000.000.00
Long-term debt repaid0.000.000.000.000.00
Common stock issued0.000.000.000.000.00
Common stock repurchased1.00B+0.0%1.00B0.000.000.00
Dividends paid0.000.000.000.000.00
Net change in cash-140M-128.6%490M+98.6%247M+271.2%66.4M-57.5%156M+51933.3%
Interest paid13.5M-66.4%40.2M-28.2%56.0M+92.4%29.1M+79.6%16.2M-21.7%
Income taxes paid313M-21.8%401M+20.5%333M+20.6%276M+79.8%153M+65.2%
Valuation Ratiosas ofDec 31 ’25as ofDec 31 ’24as ofDec 31 ’23as ofDec 31 ’22as ofDec 31 ’21
Market cap21.3B+34.4%15.8B+53.1%10.3B-18.5%12.7B+30.0%9.75B+44.3%
P/E15.9×+20.4%13.2×+15.3%11.5×-35.9%17.9×-12.5%20.5×+56.1%
P/S6.7×+21.5%5.5×+17.3%4.7×-31.2%6.8×+17.8%5.8×+27.0%
P/B3.0×+22.1%2.5×+35.7%1.8×-34.9%2.8×+12.8%2.5×+23.7%
P/FCF20.4×+39.6%14.6×+8.3%13.5×-27.6%18.7×-8.6%20.4×+110.5%
Earnings yield6.3%-16.9%7.6%-13.2%8.7%+56.0%5.6%+14.3%4.9%-35.9%
FCF yield4.9%-28.4%6.8%-7.6%7.4%+38.1%5.4%+9.4%4.9%-52.5%
Source filing10-K10-K10-K10-K10-K
Fiscal yearCEOTotal, as reportedActually paidOther executives, average$100 in the stock$100 in peers
FY2025Martine Rothblatt$18M$149.9M$9.4M$321.00$200.89
FY2024—$23M$120.3M$10M$232.45$156.19
FY2023—$17M−$10.8M$7M$144.86$143.88
FY2022—$5.3M$41.2M$2.4M$183.21$138.51
FY2021—$3.5M$50.4M$2M$142.35$124.39
FY2020—$4.8M$49.9M$4.1M——

From the pay-versus-performance table of each proxy statement (DEF 14A), the newest that states the year. “Actually paid” values stock awards at the year’s closing price, so it falls when the stock does. A year two chief executives shared lists each one’s pay, as reported / actually paid, and the totals are both. $100 in the stock and in the peer group the proxy names are the newest proxy’s, from the start of its first year.

About this data

Source: UTHR’s SEC filings (10-K / 10-Q). Annual columns are as-reported fiscal years; quarterly columns are as-reported fiscal quarters (Q4 derived as full-year minus the first three quarters where a company doesn’t file a standalone Q4); TTM (quarterly) rolls the trailing four quarters at every quarter end, TTM (yearly) samples that one year apart; balance-sheet rows show the period-end balance. Valuation ratios are sampled as of each period end. View all UTHR filings on SEC EDGAR → Not investment advice.